卵巢癌类器官模型的研究进展和治疗新策略

doi:10.11904/j.issn.1002-3070.2022.04.010

Abstract

Abstract: Ovarian cancer is one of three major malignant tumors from female reproductive system in the world,which seriously threatens the life and health of women.In recent years,researchers have continued to improve the treatment of ovarian cancer,but the five-year survival rate of ovarian cancer are still not optimistic.With the implementation of precision medicine,the pre-clinical study of organoid body models has gradually entered the field of scientific researchers'vision.The purpose of this article is to introduce the highly maintained tumor heterogeneity of ovarian cancer related to experimental organoids,simulating tumor hypoxia microenvironment,simulating tumor occurrence and metastasis,drug screening and precision medicine,gene editing system,and stimulating disease.The establishment of organoid body model library can improve the development direction of ovarian cancer treatment.With the combination with 3D bio-printing and organoids,it is expected to become a new approach for drug screening in the future.

Key words: Ovarian cancer, Organoid body model, Tumor microenvironment, Precision medicine, 3D bio-printing technology

CLC Number:

R737.31

SUN Fusheng, XU Ye, ZHANG Yongjian, LOU Ge. Research progress and new treatment strategies of ovarian cancer organoids[J]. Journal of Practical Oncology, 2022, 36(4): 346-350.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.04.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I4/346

References

1 Liu HD,Xia BR,Jin MZ,et al.Organoid of ovarian cancer:genomic analysis and drug screening[J].Clin Transl Oncol,2020,22(8):1240-1251.
2 Armstrong DK,Alvarez RD,Bakkum-Gamez JN,et al.NCCN guidelines insights:ovarian cancer,version 1.2019[J].J Natl Compr Canc Netw,2019,17(8):896-909.
3 Ma J,Ren S,Ding J,et al.Expression of RRBP1 in epithelial ovarian cancer and its clinical significance[J].Biosci Rep,2019,39(7):20190656.
4 Bowtell DD,Böhm S,Ahmed AA,et al.Rethinking ovarian cancer II:reducing mortality from high-grade serous ovarian cancer[J].Nat Rev Cancer,2015,15(11):668-679.
5 Kuroki L,Guntupalli SR.Treatment of epithelial ovarian cancer[J].BMJ,2020,371:3773.
6 Maenhoudt N,Defraye C,Boretto M,et al.Developing organoids from ovarian cancer as experimental and preclinical models[J].Stem Cell Reports,2020,14(4):717-729.
7 de Witte CJ,Espejo Valle-Inclan J,Hami N,et al.Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter-and intrapatient drug responses[J].Cell Rep,2020,31(11):107762.
8 Narod SA,Sopik V.Is invasion a necessary step for metastases in breast cancer?[J].Breast Cancer Res Treat,2018,169(1):9-23.
9 Wang R,Zhu Y,Liu X,et al.The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer[J].BMC Cancer,2019,19(1):1091.
10 Narod SA.Personalised medicine and population health:breast and ovarian cancer[J].Hum Genet,2018,137(10):769-778.
11 Jackson SE,Chester JD.Personalised cancer medicine[J].Int J Cancer,2015,137(2):262-266.
12 Lheureux S,Braunstein M,Oza AM.Epithelial ovarian cancer:evolution of management in the era of precision medicine[J].CA Cancer J Clin,2019,69(4):280-304.
13 Nero C,Vizzielli G,Lorusso D,et al.Patient-derived organoids and high grade serous ovarian cancer:from disease modeling to personalized medicine[J].J Exp Clin Cancer Res,2021,40(1):116.
14 Huch M,Koo BK.Modeling mouse and human development using organoid cultures[J].Development,2015,142(18):3113-3125.
15 Huch M,Knoblich JA,Lutolf MP,et al.The hope and the hype of organoid research[J].Development,2017,144(6):938-941.
16 Rossi G,Manfrin A,Lutolf MP.Progress and potential in organoid research[J].Nat Rev Genet,2018,19(11):671-687.
17 Dutta D,Heo I,Clevers H.Disease modeling in stem cell-derived 3D organoid systems[J].Trends Mol Med,2017,23(5):393-410.
18 Nanki Y,Chiyoda T,Hirasawa A,et al.Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing[J].Sci Rep,2020,10(1):12581.
19 Maru Y,Hippo Y.Current status of patient-derived ovarian cancer models[J].Cells,2019,8(5):505.
20 Lõhmussaar K,Boretto M,Clevers H.Human-derived model systems in gynecological cancer research[J].Trends Cancer,2020,6(12):1031-1043.
21 Maru Y,Tanaka N,Itami M,et al.Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors[J].Gynecol Oncol,2019,154(1):189-198.
22 Kopper O,de Witte CJ,Lõhmussaar K,et al.An organoid platform for ovarian cancer captures intra-and interpatient heterogeneity[J].Nat Med,2019,25(5):838-849.
23 Hui L,Chen Y.Tumor microenvironment:sanctuary of the devil[J].Cancer Lett,2015,368(1):7-13.
24 Duan Q,Zhang H,Zheng J,et al.Turning cold into hot:Firing up the tumor microenvironment[J].Trends Cancer,2020,6(7):605-618.
25 Cao K,Zhang G,Zhang X,et al.Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response[J].Oncoimmunology,2021,10(1):1969075.
26 Kast V,Loessner D.3D models for ovarian cancer[J].Adv Exp Med Biol,2021,1330:139-149.
27 Ramamoorthy P,Thomas SM,Kaushik G,et al.Metastatic tumor-in-a-dish,a novel multicellular organoid to study lung colonization and predict therapeutic response[J].Cancer Res,2019,79(7):1681-1695.
28 Hart PC,Bajwa P,Kenny HA.Modeling the early steps of ovarian cancer dissemination in an organotypic culture of the human peritoneal cavity[J].Adv Exp Med Biol,2021,1330:75-94.
29 Zhang S,Dolgalev I,Zhang T,et al.Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma[J].Nat Commun,2019,10(1):5367.
30 Bi J,Newtson AM,Zhang Y,et al.Successful patient-derived organoid culture of gynecologic cancers for disease modeling and drug sensitivity testing[J].Cancers(Basel),2021,13(12):2901.
31 McCorkle JR,Gorski JW,Liu J,et al.Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer[J].PLoS One,2021,16(8):e0254205.
32 Gorski JW,Zhang Z,McCorkle JR,et al.Utilizing patient-derived epithelial ovarian cancer tumor organoids to predict carboplatin resistance[J].Biomedicines,2021,9(8):1021.
33 Wan C,Keany MP,Dong H,et al.Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high-grade serous ovarian cancer[J].Cancer Res,2021,81(1):158-173.
34 Hill SJ,Decker B,Roberts EA,et al.Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids[J].Cancer Discov,2018,8(11):1404-1421.
35 Zhang S,Iyer S,Ran H,et al.Genetically defined,syngeneic organoid platform for developing combination therapies for ovarian cancer[J].Cancer Discov,2021,11(2):362-383.
36 Jabs J,Zickgraf FM,Park J,et al.Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations[J].Mol Syst Biol,2017,13(11):955.
37 Hoffmann K,Berger H,Kulbe H,et al.Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment[J].EMBO J,2020,39(6):104013.
38 Morgan KM,Riedlinger GM,Rosenfeld J,et al.Patient-derived xenograft models of non-small cell lung cancer and their potential utility in personalized medicine[J].Front Oncol,2017,7:2.
39 Workman MJ,Mahe MM,Trisno S,et al.Engineered human pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system[J].Nat Med,2017,23(1):49-59.
40 Curvello R,Alves D,Abud HE,et al.A thermo-responsive collagen-nanocellulose hydrogel for the growth of intestinal organoids[J].Mater Sci Eng C Mater Biol Appl,2021,124:112051.
41 Nagle PW,Plukker JTM,Muijs CT,et al.Patient-derived tumor organoids for prediction of cancer treatment response[J].Semin Cancer Biol,2018,53:258-264.
42 Murphy SV,Atala A.3D bioprinting of tissues and organs[J].Nat Biotechnol,2014,32(8):773-785.
43 Ong LJY,Islam A,DasGupta R,et al.A 3D printed microfluidic perfusion device for multicellular spheroid cultures[J].Biofabrication,2017,9(4):45005.
44 Laronda MM,Rutz AL,Xiao S,et al.A bioprosthetic ovary created using 3D printed microporous scaffolds restores ovarian function in sterilized mice[J].Nat Commun,2017,8:15261.
45 Xu F,Celli J,Rizvi I,et al.A three-dimensional in vitro ovarian cancer coculture model using a high-throughput cell patterning platform[J].Biotechnol J,2011,6(2):204-212.

[1]	LIU Xinxin, YAO Xinhui, SUN Yuefeng, MIU Meiqi, CHEN Jing. Research progress in the role of chemokine CCL20 in breast cancer microenvironment [J]. Journal of Practical Oncology, 2022, 36(3): 250-254.
[2]	CHEN Su, SUI Hong. Research progress of anti-HER2 therapy in metastatic colorectal cancer [J]. Journal of Practical Oncology, 2022, 36(3): 288-292.
[3]	YIN Yi, OU Chaoyang, HE Aiqin. Expression of GAB2 in ovarian cancer and its correlation with prognosis [J]. Journal of Practical Oncology, 2022, 36(2): 150-155.
[4]	LIU Yu, YU Xingxin, GENG Zhida, CHEN Zhengliang, HUI Peng, LIANG Yingjian. The role of liver fibroblasts in the occurrence and development of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2022, 36(2): 167-172.
[5]	DONG Lina, LIANG Tian, ZHANG Xian, ZHANG Guangmei. Research progress on tropism of ovarian cancer to fat-rich omentum organs [J]. Journal of Practical Oncology, 2022, 36(1): 54-58.
[6]	SHI Runze, LI Zhigao. Research progress of precision medical strategy for different subtypes of triple negative breast cancer [J]. Journal of Practical Oncology, 2021, 35(6): 529-533.
[7]	MU Guannan, MA Qiang. The role of NK cell polarization in endometrial cancer [J]. Journal of Practical Oncology, 2021, 35(6): 534-537.
[8]	LONG Yuanhui, CHEN Xuesong. Research progress on the effect of psychological stress on immune cells in tumor microenvironment [J]. Journal of Practical Oncology, 2021, 35(5): 436-440.
[9]	ZHANG Wenwen,JIANG Liangliang,WANG Jing. Application prospect of CAR-T therapy in ovarian cancer [J]. Journal of Practical Oncology, 2021, 35(1): 59-63.
[10]	HOU Jianying,ZHU Wei. Research progress of immunosuppressive PD-1/PD-L1 in treatment of ovarian cancer [J]. Journal of Practical Oncology, 2020, 34(3): 266-270.
[11]	LIANG Yongqin, ZHAO Hongwei. Application progress of antiangiogenic drugs in platinum-resistant ovarian cancer [J]. Journal of Practical Oncology, 2020, 34(1): 60-63.
[12]	HUANG Li, LONG Youmei, FU Yixia, XIA Liangbin. Effect of pterostilbene on apoptosis and glycolysis of ovarian cancer SKOV3 cells and its mechanism [J]. Journal of Practical Oncology, 2019, 33(6): 502-507.
[13]	DENG Mingxin, ZHANG Ying. Research progress of circRNAs and ovarian cancer [J]. Journal of Practical Oncology, 2019, 33(6): 549-552.
[14]	ZHANG Huiting, LOU Ge. Research progress in 3D cell culture model of ovarian cancer tumor microenvironment [J]. Journal of Practical Oncology, 2019, 33(6): 557-560.
[15]	SONG Ling, FU Qiong. Astragalin inhibits hypoxia-induced proliferation and invasion of ovarian cancer cells by up-regulating PHD2 [J]. Journal of Practical Oncology, 2019, 33(5): 407-414.

Research progress and new treatment strategies of ovarian cancer organoids

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments